Posted: Thursday, September 21, 2023
Combination therapy with the monoclonal antibody daratumumab plus pomalidomide and low-dose dexamethasone significantly improved overall survival in patients with relapsed or refractory multiple myeloma who were previously treated with lenalidomide, according to the results of the phase II MM-014 study, which were presented at the 2023 Society of Hematologic Oncology (SOHO) Annual Meeting (Abstract MM-371) and published in Clinical Lymphoma, Myeloma, & Leukemia. Treatment-related safety remained consistent across all trials, supporting the use of this combined therapy approach in this patient population to improve clinical outcomes, commented Nizar J. Bahlis, MD, of the University of Calgary, Canada, and colleagues.
A total of 112 patients were recruited from cohort B of the phase II MM-014 trial. These patients had relapsed or refractory multiple myeloma and had previously received treatment with one (n = 69) or two (n = 43) lines of therapy, with lenalidomide therapy being the most recent treatment received. All patients were treated with 4 mg of pomalidomide, 40 mg of dexamethasone, and 16 mg/kg by body weight of daratumumab.
The study authors reported an overall survival of 56.7 months in patients with lenalidomide-refractory disease (n = 85) and 53.6 months in patients with lenalidomide-relapsed disease (n = 27). In addition, the most common treatment-related adverse event experienced by patients was neutropenia. Pomalidomide dosing was reduced in 15.2% of patients and interrupted in 33.9% of patients secondary to neutropenia. Similarly, daratumumab was interrupted in 26.8% of patients because of neutropenia. Dexamethasone was reduced in 8.9% of patients and interrupted in 0.9% of patients secondary to insomnia.
Disclosure: The study authors report no conflicts of interest.